SEC filing summary
Issuer identity discrepancy: The request identifies Cypherpunk Technologies Inc., but the supplied Form 10-K is for Leap Therapeutics, Inc. (Nasdaq: LPTX). This summary reflects the filing text, not the named company.
Business context and reporting period
This is Leap Therapeutics’ annual report for the fiscal year ended December 31, 2018, filed April 1, 2019. Leap is a clinical-stage biotechnology company developing cancer therapies. Its lead investigational candidates are DKN-01, an anti-DKK1 antibody, and TRX518, a GITR agonist antibody. Neither had been approved for sale, and the company reported no product revenue.
Financial results and liquidity
| Metric | 2018 | 2017 |
|---|---|---|
| Revenue from product sales | None | None |
| Research and development expense | $21.8 million | $22.5 million |
| General and administrative expense | $8.9 million | $9.8 million |
| Total operating expenses | $30.8 million | $32.4 million |
| Net loss | $23.1 million | $29.7 million |
| Basic loss per share | $1.64 | $3.27 |
| Cash used in operating activities | $26.0 million | $22.1 million |
| Cash and cash equivalents at year-end | $16.3 million | $25.7 million |
The smaller 2018 net loss was helped substantially by a $7.3 million noncash gain from remeasuring the warrant liability; operating loss was $30.8 million. The liability fell to $3.4 million from $11.9 million at year-end 2017. Foreign-currency results also swung from a $0.8 million gain in 2017 to a $0.8 million loss in 2018. Australian R&D incentive income declined to $0.8 million from $1.7 million.
At December 31, 2018, current assets were $17.3 million and current liabilities $6.5 million, implying working capital of approximately $10.9 million. Total liabilities were $9.9 million, including the $3.4 million warrant liability; no conventional borrowing was reported at year-end. Stockholders’ equity was $9.2 million. The filing does not provide a meaningful product gross margin; the company had no product sales.
Operating cash outflow exceeded the net loss, while financing provided $15.9 million, mainly from the March 2018 stock offering and warrant exercises. Cash declined by $9.5 million during the year. Contractual obligations at year-end included $1.9 million of lease commitments and $0.2 million of noncancelable research/manufacturing commitments.
Changes versus the prior period
- Net loss improved by $6.6 million, but this reflected the larger noncash warrant remeasurement gain as well as lower operating expenses; cash used in operations increased by $3.9 million.
- R&D expense decreased $0.7 million overall: DKN-01 spending rose to $15.6 million from $15.3 million, while TRX518 spending fell to $6.2 million from $7.2 million. Management cited lower manufacturing and stock-compensation costs, partly offset by increased clinical-trial spending and enrollment.
- G&A expense fell $0.9 million, primarily because 2017 included higher stock-based compensation related to the Macrocure merger.
- Cash fell from $25.7 million to $16.3 million, and total assets declined from $29.1 million to $19.1 million.
Outlook, risks, and unusual items
- Funding: After year-end, Leap raised approximately $12.1 million net in a February 2019 public offering. Management said year-end cash, offering proceeds, and expected Australian R&D incentive receipts would fund operations for at least 12 months from issuance of the financial statements. It expects continued losses and says further capital or collaboration funding will be needed; failure to obtain funding could force trial reductions or delays.
- Development: The company planned continued DKN-01 and TRX518 clinical development and expected expenses to increase. No specific revenue, earnings, or cash-flow guidance was provided. DKN-01 studies included esophagogastric, gynecologic, and biliary-tract cancer programs; TRX518 was being studied alone and in combinations. Reported early patient responses are preliminary and do not establish efficacy or approval prospects.
- Warrants and dilution: The February 2019 offering triggered a full-ratchet adjustment of the 2017 warrants’ exercise price to $1.75. The offering also issued 7.56 million shares and warrants for an equal number of shares, creating potential dilution. The warrant accounting produced a material, noncash effect on 2018 earnings.
- Nasdaq listing: In January 2019, Leap received notice that its market value of listed securities was below the $50 million minimum, with a compliance deadline of July 23, 2019. The company was evaluating options to regain compliance.
- Intellectual property: European opposition proceedings narrowed claims on one TRX518 patent; a separate European patent covering TRX518 combinations with chemotherapy was revoked by the opposition division. Leap appealed both outcomes. The filing identifies potential limits to European exclusivity and material legal costs.
- Other principal risks: Clinical and regulatory failure, enrollment and trial delays, dependence on third-party manufacturers and research organizations, competition, additional financing and dilution, and uncertain eligibility or availability of Australian R&D incentives. The filing reported no other material legal proceedings.
- Controls and audit: Management concluded disclosure controls and internal control over financial reporting were effective at December 31, 2018. The auditor issued an unqualified opinion on the financial statements; no auditor attestation on internal controls was included under the emerging-growth-company exemption.
Most important facts for investors to verify
- Confirm the issuer: the supplied filing is Leap Therapeutics’ 2018 Form 10-K, not a filing for Cypherpunk Technologies Inc.
- Review the full financial statements and notes, particularly operating cash burn, warrant-liability valuation and post-offering dilution.
- Check subsequent cash, spending, and financing needs against management’s stated minimum 12-month runway assessment.
- Assess later clinical-trial data in context of small, open-label studies and confirm trial status, enrollment, safety, and endpoints.
- Verify Nasdaq listing compliance and the outcomes of the European patent appeals.